Evidence map›Paper›PMID 42737535›Full record

ArticleInternational journal of molecular sciences2026

Crosstalk Between mTOR and NF-κB Signaling Pathways in Clear Cell Renal Cell Carcinoma.

Melanie Glueck, Alexandra Lucaciu, Sumedha Inukollu, Rushendhiran Kesavan, Amelie Janssen, Josef Pfeilschifter, Julien Subburayalu, Ramesh K Krishnan, Rajkumar Vutukuri

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Melanie GlueckInstitute of General Pharmacology and Toxicology, Pharmazentrum Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany.
Alexandra LucaciuInstitute of General Pharmacology and Toxicology, Pharmazentrum Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany.ORCID 0000-0001-5783-088X
Sumedha InukolluDepartment of Bioinformatics, Pondicherry University, Puducherry 605014, India.ORCID 0009-0006-1948-7148
Rushendhiran KesavanChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.ORCID 0000-0002-8540-8093
Amelie JanssenInstitute of General Pharmacology and Toxicology, Pharmazentrum Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany.
Josef PfeilschifterInstitute of General Pharmacology and Toxicology, Pharmazentrum Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany.
Julien SubburayaluDepartment of Internal Medicine, University Hospital Carl Gustav Carus TU Dresden, Fetscherstraße 74, 01307 Dresden, Germany.ORCID 0000-0001-9243-0558
Ramesh K KrishnanDepartment of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany.
Rajkumar VutukuriInstitute of General Pharmacology and Toxicology, Pharmazentrum Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany.ORCID 0000-0002-7890-9471

Funding

Deutsche Forschungsgemeinschaft SFB1039
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive type of renal cell carcinoma (RCC), representing approximately 80% of cases globally. Despite improved diagnosis and therapy, treatment of aggressive or metastatic ccRCC remains challenging due to acquisition of primary or secondary resistance. Among the dysregulated signaling mechanisms identified in ccRCC, the mechanistic target of rapamycin (mTOR) and the nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) pathways play central roles in regulating various biological functions such as metabolism, inflammation, tumor growth, and survival. However, the molecular crosstalk between mTOR and NF-κB signaling in ccRCC progression and therapeutic resistance remains poorly understood. Therefore, in our current study, we aimed to investigate the interplay between mTOR and NF-κB signaling in ccRCC. We analyzed tumor tissue samples from human ccRCC patients. For validation of mTOR and NF-κB signaling, we used two human ccRCC cell lines, A498 and 786-O. Using pharmacological inhibitors of mTOR and IKK/NF-κB signaling, Torin-1 and MLN120B, respectively, we assessed the functional relationship between these two pathways employing immunoblotting, EdU-based immunocytochemistry, and functional assays. Our findings reveal that both mTOR and NF-κB pathways are aberrantly activated in human ccRCC tissues. Phosphorylation of IκBα, S6, and 4E-BP1 was increased compared with matched adjacent control tissue. In A498 and 786-O cells, pharmacological inhibition of mTOR or IKK/NF-κB altered key readouts of the reciprocal pathway, including AKT, S6, 4E-BP1, IκBα and p65 phosphorylation. Both inhibitors reduced cell number and EdU incorporation, with stronger anti-proliferative effects observed after Torin-1 treatment. Pharmacological inhibition of either pathway altered key readouts of the other pathway, supporting a reciprocal functional association between mTOR- and NF-κB-associated signaling in the ccRCC models analyzed. Our findings support a functional association between mTOR- and NF-κB-associated signaling in the ccRCC models and provide a rationale for further mechanistic studies evaluating combined pathway modulation.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNF-kappa BSignal TransductionTOR Serine-Threonine KinasesCell Line, TumorCell ProliferationHumansPhosphorylationMTOR protein, humanNF-kappa BTOR Serine-Threonine Kinasescell proliferationinflammationmTOR signalingNF-κB signalingrenal cell carcinoma

Identifiers

PMID42737535
PMCPMC13566279

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.